ChemoSen3D utilizes proprietary magnetic 3D bioprinting technology to create patient-derived spheroids for ex vivo chemosensitivity testing, enabling precise identification of effective cancer treatments based on individual tumor responses. This approach addresses the issue of ineffective and toxic cancer therapies by providing tailored treatment recommendations that minimize unnecessary drug exposure and associated side effects.
Funding
$165K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatment selection often relies on genetic profiling, which may not accurately predict individual patient responses to specific drugs. This can lead to ineffective treatments, unnecessary side effects, financial burden, and reduced lifespan for patients, especially those with rare or recurring cancers.
Solution
ChemoSen3D offers a personalized approach to cancer treatment selection by utilizing a proprietary magnetic 3D bioprinting platform to create patient-derived spheroids. These spheroids are then used in ex vivo chemosensitivity assays to determine the effectiveness of various anti-cancer agents on a per-patient basis. By combining functional cell-based assays with genetic testing assets, ChemoSen3D provides comprehensive treatment recommendations based on individual tumor responses, enabling physicians to select the most effective and targeted therapies for their patients. This approach aims to minimize exposure to ineffective and toxic drugs, improve treatment outcomes, and enhance the quality of life for cancer patients.
Target Audience
The primary audience includes oncologists, clinicians, and researchers seeking personalized treatment options for cancer patients, as well as pharmaceutical companies interested in advanced drug development and screening platforms.
Features
- Proprietary magnetic 3D bioprinting technology for rapid and efficient cell manipulation
- Patient-derived spheroid creation that maintains tissue heterogeneity for physiologically relevant drug response determination
- Ex vivo chemosensitivity testing to identify reactive therapies on a per-patient basis
- Functional cell-based assays combined with genetic testing for comprehensive treatment recommendations
- Validated, scalable, and differentiated 3D cell culture for robust research and therapeutic applications
- Minimal sample requirements, maximizing research value from limited and precious samples
- Data-rich platform for creating AI models, empowering advanced drug development through machine learning
- Personalized tumor response profiles to improve patient outcomes